Please assess the completion status of the following clinical trial:

Trial Title: Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has a cytologically or histologically and radiologically confirmed, advanced, recurrent, or metastatic solid tumor of the nine types listed below:~  * Pancreatic Cancer~ * Castration-Resistant Prostate Cancer (CRPC)~ * Hepatocellular Carcinoma (HCC)~ * Gastric or Gastroesophageal Junction Cancer~ * Melanoma~ * Small Cell Lung Cancer (SCLC)~ * Ovarian cancer, primary peritoneal or fallopian tube carcinoma~ * Breast cancer that is one of the following subtypes: estrogen receptor positive breast cancer, estrogen receptor/progesterone receptor/HER2-negative (triple-negative), or inflammatory (regardless of receptor status) disease histology~ * Non-Small Cell Lung Cancer (NSCLC)~* Certain requirements for prior therapies may apply~* The subject has documented progressive disease at screening~* Subjects having any tumor type of other than CRPC must have at least one lesion that is not within a previously irradiated field and is measurable on CT or MRI scan~* The subject has recovered to baseline or CTCAE ≤ Grade 1 from toxicities related to prior treatment (some exceptions apply)~* The subject is ≥ 18 years old on the day of consent~* Tissue samples from archival or fresh tissue, or a tissue block of the subject's tumor~* The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* The subject has adequate organ function~* The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document~* Sexually active fertile subjects (male and female), and their partners, must agree to use medically accepted methods of contraception during the course of the study and for 3 months after the last dose of the study drug(s)~* Female subjects of childbearing potential must have a negative pregnancy test at screening~Exclusion Criteria:~* The subject has experienced clinically-significant hematemesis or hemoptysis of \>0.5 teaspoon of red blood, or other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment~* The subject has a cavitating pulmonary lesion(s) or a pulmonary lesion abutting or encasing a major blood vessel~* Certain restrictions on prior treatments apply~* The subject has known symptomatic or uncontrolled brain metastases or epidural disease~* The subject has prothrombin time/International Normalized Ratio (PT/INR) or partial thromboplastin time (PTT) test results that are above (1.3x)the laboratory upper limit of normal~* The subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or Coumadin-related agents, heparin, thrombin or FXa inhibitors, and antiplatelet agents (low-dose aspirin (≤81 mg/day), low-dose warfarin (≤1mg/day, and prophylactic low molecular weight heparin (LMWH) are permitted)~* The subject has a corrected QT interval(QTcF)\>500 ms at screening~* The subject has uncontrolled, significant intercurrent illness~* The subject is unable to swallow capsules~* The subject is pregnant or breastfeeding~* The subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulation~* The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee~* The subject has had another diagnosis of malignancy requiring systemic treatment within the last two years, unless non-melanoma skin cancer, in-situ carcinoma of the cervix, or superficial bladder cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lead-in Stage - cabozantinib (XL184) (Type: EXPERIMENTAL): Open Label, cabozantinib, 100 mg, po QD for 12 weeks.
- Randomized Stage - cabozantinib (XL184) (Type: EXPERIMENTAL): Blinded, cabozantinib, 100 mg, po QD until disease progression.
- Randomized Stage - placebo (Type: PLACEBO_COMPARATOR): Blinded, placebo, 100 mg, po QD until disease progression.
- Open-Label Extension - cabozantinib (XL184) (Type: EXPERIMENTAL): Open Label, cabozantinib, for subjects that were on placebo during the randomized stage, 100 mg, po QD until disease progression or unacceptable toxicity.
- Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 100mg (Type: EXPERIMENTAL): Open Label, cabozantinib, 100 mg, po QD until disease progression or unacceptable toxicity.
- Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 39.4mg (Type: EXPERIMENTAL): Open Label, cabozantinib, 39.4, po QD until disease progression or unacceptable toxicity.
- A. Non-Randomized Expansion (NRE) Cohort - Ovarian (Type: EXPERIMENTAL): Open Label, cabozantinib, 100 mg, po QD until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete